We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
News

Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists

Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
News

Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abstract
Although there is no shortage of potential drug targets, there are only a handful known low-molecular-weight inhibitors of protein-protein interactions (PPIs). One problem is that current efforts are dominated by low-yield high-throughput screening, whose rigid framework is not suitable for the diverse chemotypes present in PPIs. Here, we developed a novel pharmacophore-based interactive screening technology that builds on the role anchor residues, or deeply buried hot spots, have in PPIs, and redesigns these entry points with anchor-biased virtual multicomponent reactions, delivering tens of millions of readily synthesizable novel compounds. Application of this approach to the MDM2/p53 cancer target led to high hit rates, resulting in a large and diverse set of confirmed inhibitors, and co-crystal structures validate the designed compounds. Our unique open-access technology promises to expand chemical space and the exploration of the human interactome by leveraging in-house small-scale assays and user-friendly chemistry to rationally design ligands for PPIs with known structure.

This paper is published online in PLos ONE and is free to access.

Advertisement